局部进展期直肠癌的强化治疗：对病理完全缓解和结局的影响。
Treatment Intensification for Locally Advanced Rectal Cancer: Impact on Pathological Complete Response and Outcomes.
机构信息
Department of Radiation Oncology, SS. Annunziata Hospital, G. D'Annunzio University, Chieti, Italy.
Department of Radiation Oncology, SS. Annunziata Hospital, G. D'Annunzio University, Chieti, Italy
出版信息
In Vivo. 2020 May-Jun;34(3):1223-1233. doi: 10.21873/invivo.11896.
AIM
Pathological complete response (pCR) and clinical outcomes [overall survival (OS), disease-free survival (DFS), locoregional control (LC)] were evaluated in a single-institution experience of different schedules of neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancer (LARC).
PATIENTS AND METHODS
Data for 322 patients with LARC were retrospectively analyzed. pCR was evaluated according to Mandard tumor regression grade (TRG). The Kaplan-Meier method was used to estimate OS, DFS and LC.
RESULTS
Three hundred and three (94.1%) patients underwent surgery. pCR was observed in 81 patients (26.7%), with TRG1-2 rate of 41.8%. The 5- and 10-year OS, DFS and LC rates were 82.5%±2.5% and 65.5%±3.8%, 81.2%±2.4% and 79.3%±2.9%, 93.1%±1.7% and 90.5%±2.1%, respectively.
CONCLUSION
Neoadjuvant CRT in LARC patients resulted in favorable long-term oncological outcomes, with a high pCR rate and acceptable toxicity.
目的
评估局部晚期直肠癌（LARC）患者接受不同新辅助放化疗（CRT）方案的单中心经验中的病理完全缓解（pCR）和临床结果[总生存（OS）、无病生存（DFS）、局部区域控制（LC）]。
方法
回顾性分析了 322 例 LARC 患者的数据。根据 Mandard 肿瘤消退分级（TRG）评估 pCR。采用 Kaplan-Meier 法估计 OS、DFS 和 LC。
结果
303 例（94.1%）患者接受了手术。81 例（26.7%）患者观察到 pCR，TRG1-2 率为 41.8%。5 年和 10 年 OS、DFS 和 LC 率分别为 82.5%±2.5%和 65.5%±3.8%、81.2%±2.4%和 79.3%±2.9%、93.1%±1.7%和 90.5%±2.1%。
结论
LARC 患者的新辅助 CRT 带来了良好的长期肿瘤学结果，pCR 率高，毒性可接受。
Zotero 插件